Financing innovation: proposal for novel adaptive platform trial fund offers new model for ALS drug development
Peer-Reviewed Publication
Updates every hour. Last Updated: 7-Oct-2025 13:11 ET (7-Oct-2025 17:11 GMT/UTC)
Researchers have introduced a new approach to funding clinical trials for amyotrophic lateral sclerosis (ALS) therapies. The study “Financing Drug Development via Adaptive Platform Trials,” published today in PLOS One, outlines a financing model that merges the efficiencies of adaptive platform trials — lower costs and shorter durations — with an innovative royalty-based investment structure designed to accelerate therapeutic development for ALS and other serious diseases.
Your mouth is a magician. Bite the inside of your cheek, and the wound may vanish without a trace in a couple of days. A preclinical study co-led by Cedars-Sinai, Stanford Medicine and the University of California, San Francisco (UCSF), has discovered one secret of this disappearing act. The findings, if confirmed in humans, could one day lead to treatments that enable rapid, scarless recovery from skin wounds on other parts of the body.
Prenatal exposure to ambient fine particulate matter and climatic factors, such as temperature and rainfall, are associated with adverse birth outcomes in India, according to a study published July 2nd, 2025, in the open-access journal PLOS Global Public Health by Mary Abed Al Ahad from the University of St Andrews, U.K.
A study by scientists at the University of Colorado Anschutz Medical Campus reveals that joint tissue from patients with early-stage rheumatoid arthritis often have high levels of a protein called granzyme used by the immune system to attack pathogens.